REVIEWER
PROFESSIONAL
EXECUTIVE
CORTELLIS
COMPETITIVE INTELLIGENCE
MODULES
•
•
•
Drugs
Summaries of 62,000+ products and therapeutic research programs, from pre-clinical
development through launch. Details of name, companies, indications, target, mechanism
of action, chemical structure, and current development status.
optional
•
•
Drugs Expanded
Expanded profiles of drugs, adding detailed development history, current regulatory and
patent position, historical and forecast sales, and SWOT analysis.
•
•
•
•
Companies
Names and addresses of 123,000+ companies in the pharma, biotech, and related sectors,
showing number of drugs in development, number of deals, and number of patents. Text
profiles of those companies with drugs in development.
Companies Expanded
Expanded profiles of companies, describing partnerships, historical and forecast sales,
company financials, and stock price charts.
Broker Research –
Search-only Access
Searchable access to analyst reports written by investment brokers, fully indexed to
Cortellis™ Drug and Company content.
Broker Research –
Full Access
Analyst reports written by investment brokers. Broker Research reports provide unique
insight, including forecast and opinions from industry experts. Thomson Reuters has the
largest sell-side embargoed broker research collection on the market: 1,600 brokers, 30
of which are exclusive to Thomson Reuters. Fully indexed to Cortellis Drug and Company
content. Full PDFs of reports available for download.
Event Transcripts –
Search-only Access
Searchable access to transcripts of calls/meetings where pharmas/biotechs reveal news
and field questions from analysts and reporters. Provides up to 500 words of the relevant
section of a transcript. Fully indexed to Cortellis Drug and Company content.
Event Transcripts –
Full Access
Transcripts of calls/meetings where pharmas/biotechs reveal news and field questions
from analysts and reporters. Fully indexed to Cortellis Drug and Company content. Full
transcript including Q&A is provided.
Venture Funding –
Search-only Access
Searchable access to corporate and private VCs, their invested companies, and total funds
in life sciences, along with their last investment date and the amount invested.
Venture Funding –
Full Access
Full access to corporate and private VCs, firm profiles, investments they’ve made, and
co-investors, together with the performance of their portfolio companies, including their
drug pipeline, deals, and sales. Helps you gain a complete assessment of biotechnology
companies and investment trends. Venture content is integrated with company, drug
development pipeline, and deals intelligence.
Pharma-related press releases covering drug development, regulatory, generic and
patent news, and commercial and company information. Indexed by subject area, and
when applicable, indication, action, and technology. Primary and secondary drugs and
companies are also identified and indexed in order to increase pertinence of retrieval.
•
optional
optional
optional
optional
optional
optional
optional
optional
optional
optional
•
•
•
Press Releases
optional
•
•
Conferences
Reports from approximately 200 conferences and meetings each year. Additional
abstracting of presentations from around 130 major conferences.
optional
•
•
Deals
45,000+ R&D, drug development, commercialization, and other types of deals, showing
the partner companies, deal dates and status, geography, and assets involved, plus deal
structure and financials when available.
optional
•
•
Patents
All pharmaceutical patents from WO, EP, and US. Rewritten abstracts for the documents
claiming a therapeutic activity, searchable claims and structure, and links to claimed
drugs. Links to full PDF files.
Visit ip-science.thomsonreuters.com for more information.
REVIEWER
PROFESSIONAL
EXECUTIVE
CORTELLIS
COMPETITIVE INTELLIGENCE
MODULES
optional
optional
•
Patents Expanded
(Global)
All pharmaceutical patents from 90+ countries. Features expiry data and term extensions,
commercially relevant annotations, drug linking and claim indexing from emerging
markets, DWPI abstracts, and Derwent® Chemistry Resources structures.
N/A
N/A
•
Clinical Trials
Profiles of 132,000+ clinical studies associated with the U.S. National Institute of Health
ClinicalTrials.gov trial registry. These trials are searchable on their own and are also
indexed and searchable within drug profiles. An additional 90,000+ global trial profiles
are available with a Cortellis Clinical Trials Intelligence subscription which also includes
outcomes and patient segmentation indexing information.
optional
optional
•
Literature
Abstracts of scientific journal articles published from 1964, covering all aspects of drug
development, synthesis, evaluation, manufacture, and use.
Disease Briefings
Dynamic executive summaries on the current status and future trends in drug therapy
that provide information on the etiology, incidence, prevalence, diagnosis, prevention,
and treatment of more than 155 diseases ranging from acne to West Nile virus and
covering 27 therapeutic areas.
Competitive
Intelligence Matrix/
Drug Analytics
Spotfire-based visualization tool that explores the relationships between certain
parameters of drug information; for example, therapy area and parent company for a given
criterion such as a selected active indication, active company, or target-based action. The
two main analyses are the DRUG COUNTS and HIGHEST DEVELOPMENT STATUS pages.
You can also see a DEVELOPMENT FUNNEL view of the drugs.
Virtual Merger
Spotfire-based interactive visualization of the development pipeline that would emerge
from the merger of two companies.
Intellectual Property
Landscape
Spotfire-based company portfolio and drug patenting activity analysis and visualization.
Company interactions identifying joint ventures, and litigations. Patent cliff highlighting
loss of patent protection and potential generic competition.
optional
optional
optional
N/A
•
•
N/A
•
N/A
N/A
•
•
Visit ip-science.thomsonreuters.com for more information.
S028221/1-16
© 2016 Thomson Reuters
Thomson Reuters and the Kinesis logo are trademarks of Thomson Reuters.